Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked. I would want the raw data before agreeing with my own summary of it.
Documentation that appears only after payment Writing it up because I had to work it out twice and would rather nobody else did.
Proposing that documentation deserves a maintained page rather than a recurring topic, and drafting the skeleton here so that the argument about scope happens before the writing rather than after.
What I think belongs on it, what does not, and the three claims that would need a citation each.
The opening post is the version of this I will quote in future. One addition.
Adding a reference point for documentation. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked.
I would want the raw data before agreeing with my own summary of it.
Documentation is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Summarising the documentation thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
Building on post #5 rather than restating it.
Where somebody posts a concern, ask what would resolve it before arguing about it. Half of these threads end with a document nobody had asked for.
Speaking for myself and not for anyone else who has posted here.
Since documentation keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you something about systems behind the document. A certificate that is a number and a signature tells you less.
Written in the hope of being told what I have missed.
The strongest single signal available cheaply is what happens when you ask a technical question. A quantitative answer inside a working day is difficult to fake at scale.
The short answer was in the first line; everything after is the working.
Building on post #10 rather than restating it.
Careful with the language on documentation. "Not detected" and "not present" are different findings and the first is a statement about the method.
The practical version of documentation is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Post #14 is the version of this I will quote in future. One addition.
Prices well below the rest of the market are a fact rather than a finding. They are worth noting and they do not establish anything on their own.
I am confident about the direction and much less about the magnitude.
Documentation looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Answering the question post #16 raises rather than the one it answers.
A certificate that reports a specification in the result column is a documentation defect, and it is a defect people should be able to recognise without it being called anything worse.
Caveat: everything above assumes the paperwork is what it says it is.
Everything in post #21 holds. The case it does not cover is the one I have.
Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming implausible perfection without backing evidence is overreaching.
Correct me on the arithmetic if it is wrong; I would rather know.
Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is showing you something about how they operate.
Two claims get bundled together under documentation and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Useful. I have added it to my own notes with the date on it.
Post #25 answers the question as asked. The question underneath it is different.
The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into something useful and allegations do not.
The general case is well covered; this is the awkward specific one.
Safety documentation absent: a supplier that cannot provide information about sterility testing, endotoxin testing, or safety documentation when asked is raising flags.